免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema

NCT: NCT07626645 · RECRUITING

NCT識別子NCT07626645
ステータスRECRUITING
開始日2026-09-01
完了2027-02-01
SponsorGazi University (OTHER)
First posted
Last updated

概要

Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑